Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin

American Journal of Medicine

Volumn 129, Issue 6, 2016, Pages 600-607

  Senoo, Keitaro ^a   Proietti, Marco ^a   Lane, Deirdre A ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Anticoagulation; ATRIA; Bleeding; HAS BLED; ORBIT; Risk assessment

Indexed keywords

ANTIVITAMIN K; IDRAPARINUX; WARFARIN; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; GLUCURONOSYLTRANSFERASE; HAS1 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION AND RISK FACTOR IN ATRIAL FIBRILLATION SCORE; ARTICLE; ATRIAL FIBRILLATION; BLEEDING TENDENCY; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION, ABNORMAL RENAL LIVER FUNCTION, STROKE, BLEEDING HISTORY OR PREDISPOSITION, LABILE INTERNATIONAL NORMALIZED RATIO, ELDERLY, DRUGS ALCOHOL, ANTICOAGULATION AND RISK FACTOR IN ATRIAL FIBRILLATION SCORE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME REGISTRY FOR BETTER INFORMED TREATMENT SCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED; COMORBIDITY; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COMORBIDITY; FEMALE; GLUCURONOSYLTRANSFERASE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK ASSESSMENT; ROC CURVE; WARFARIN;

EID: 84960194211     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.10.001     Document Type: Article

References (19)

1. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
2. M.C. Fang, A.S. Go, Y. Chang, and et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study J Am Coll Cardiol 58 2011 395 401
3. E.C. O'Brien, D.N. Simon, L.E. Thomas, and et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation Eur Heart J 2015 Sep 29 [Epub ahead of print]
4. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
5. P. Gallego, V. Roldan, F. Marin, and et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 2013 1189 1198
6. Y. Wan, C. Heneghan, R. Perera, and et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 2008 84 91
7. M.G. Bousser, J. Bouthier, H.R. Buller, and et al. Comparison of idraparinux with vitamin k antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial Lancet 371 2008 315 321
8. S. Apostolakis, D.A. Lane, Y. Guo, H. Buller, and G.Y. Lip Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of sr34006 compared with warfarin or acenocoumarol in patients with atrial fibrillation) study J Am Coll Cardiol 60 2012 861 867
9. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
10. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
11. F. Ikeda, Y. Doi, T. Ninomiya, and et al. Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study Cardiovasc Diabetol 12 2013 164
12. National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. (clinical guideline 180) 2014. Available at: http://guidance.Nice.Org.Uk/cg180. 2014: http://guidance.nice.org.uk/CG180. Accessed September 14, 2015.
13. R. De Caterina, S. Husted, L. Wallentin, and et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Thromb Haemost 110 2013 1087 1107
14. G.Y. Lip, F. Andreotti, L. Fauchier, and et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] working group on thrombosis Thromb Haemost 106 2011 997 1011
15. V. Roldan, F. Marin, H. Fernandez, and et al. Predictive value of the has-bled and atria bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy Chest 143 2013 179 184
16. G.Y. Lip, and D.A. Lane Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors Eur Heart J 2015 Sep 8 [Epub ahead of print]
17. A.J. Camm, G.Y. Lip, R. De Caterina, and et al. 2012 focused update of the ESC Guidelines for the Management of Atrial Fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation-developed with the special contribution of the European Heart Rhythm Association Europace 14 2012 1385 1413
18. J.B. Olesen, G.Y. Lip, J. Lindhardsen, and et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study Thromb Haemost 106 2011 739 749
19. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation cohort study Circulation 125 2012 2298 2307